AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38528164
Drug: novel radiolabelled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: novel radiolabelled somatostatin receptor antagonist
Trial: 38528445
Drug: investigator choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigator choice standard therapy (ICT)
Trial: 38528456
Drug: Online adaptive
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online adaptive radiotherapy (oART) with daily automated treatment re-planning
Trial: 38528476
Drug: Lasmiditan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (various doses)
Trial: 38528476
Drug: Lasmiditan (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (dose adjustments)
Trial: 38529674
Drug: Deucravacitinib 12
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 12 mg QD
Trial: 38530160
Drug: Letrozole (LTZ)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LTZ) 15 mg daily
Trial: 38530213
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy following peri-implantitis treatment (SPIT)
Trial: 38530213
Drug: Comprehensive information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive information provided prior to peri-implantitis treatment
Trial: 38530474
Drug: 0.454% stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.454% stannous fluoride-containing dentifrice twice daily (test group, n=66)
Trial: 38530474
Drug: 5.0% calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0% calcium sodium phosphosilicate-containing dentifrice twice daily (positive control group, n=64)
Trial: 38530474
Drug: 1150 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1150 ppm NaF dentifrice twice daily (negative control group, n=67)
Trial: 38530565
Drug: epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (cisplatin plus pemetrexed, non-squamous)
Trial: 38530565
Drug: epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus pemetrexed, non-squamous)
Trial: 38530565
Drug: epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (carboplatin plus paclitaxel, squamous or non-squamous)
Trial: 38530565
Drug: epacadostat plus
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epacadostat plus pembrolizumab and chemotherapy
Trial: 38530569
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) followed by brachytherapy
Trial: 38530569
Drug: Initial tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial tumor volume (iTV) > 55.99 cc
Trial: 38530569
Drug: Restaging tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restaging tumor volume (rTV) > 6.25 cc
Trial: 38531002
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily for 52 weeks
Trial: 38531362
Drug: Three-dimensional optoacoustic
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional optoacoustic imaging in patients who received disease-modifying therapy
Trial: 38531570
Drug: Precision dosing
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision dosing of infliximab with a clinical decision support tool (RoadMAB) targeting specific trough concentrations and pharmacodynamic targets.
Trial: 38531570
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care dosing of infliximab with a modified starting dose (5 or 7.5 mg/kg based on pretreatment serum albumin) aiming for maintenance trough concentrations of 5-10 µg/mL.
Trial: 38531585
Drug: Insulin Pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Pump Therapy (IPT)
Trial: 38531585
Drug: Insulin Pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Pump Therapy (IPT) with BGM
Trial: 38531585
Drug: Insulin Pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Pump Therapy (IPT) with CGM
Trial: 38531939
Drug: Ultra-low-dose computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose computed tomography (ULD-CT)
Trial: 38531939
Drug: Surgery or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery or stereotactic body radiation therapy (SBRT)
Trial: 38532251
Drug: Text-message intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Text-message intervention combining cognitive-behavioural therapy (CBT) texts with techniques from cognitive psychology (message framing) and social psychology (growth mindsets).
Trial: 38532395
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine
Trial: 38532395
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder (MOUD) with buprenorphine/naloxone (bup/nx)
Trial: 38532451
Drug: Moderate- to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate- to vigorous-intensity physical activities combined with low-dose PK-guided EHL FVIII prophylaxis for 6 months
Trial: 38532503
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (amoxicillin 500 mg/clavulanic acid 125 mg) given after delivery
Trial: 38532768
Drug: Inhaled imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled imatinib (AV-101)
Trial: 38533127
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with one to two doses
Trial: 38533127
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with three or more doses
Trial: 38533552
Drug: Ulotaront (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulotaront (150 mg)
Trial: 38533552
Drug: Previous antipsychotic
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous antipsychotic (PA)
Trial: 38533643
Drug: Ketone ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone ester (KE) treatment for 14 days
Trial: 38533985
Drug: No TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TNF inhibitors (Control)
Trial: 38535011
Drug: Low-dose non-contrast
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose non-contrast thoracic CT
Trial: 38536082
Drug: Enzalutamide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (120 mg/d) + Relacorilant (escalating doses, RP2D of 150 mg/d)
Trial: 38536128
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day nicotinamide
Trial: 38536227
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable (LAI) HIV antiretroviral therapy (ART)
Trial: 38536227
Drug: Patient-oriented tools
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-oriented tools for comparing LAI ART and daily oral ART options
Trial: 38536442
Drug: HEV-239 (Hecolin)
RxNorm normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly on days 1, 29, and 180
Trial: 38536442
Drug: HEV-239 (Hecolin)
RxNorm normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV-239 (Hecolin) vaccine, 30 µg administered intramuscularly
Trial: 38536442
Drug: HEV-239 (Hecolin)
RxNorm normalized name: Theocolin
DrugBank: Oxtriphylline (DB01303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV-239 (Hecolin) vaccine
Trial: 38536545
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous sedation (control)
Trial: 38536810
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous infusion of dual bNAbs (VRCO1LS and 10-1074)
Trial: 38536994
Drug: intra-mucosal injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-mucosal injection of injectable platelet-rich fibrin (i-PRF)
Trial: 38536994
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (Control)
Trial: 38537155
Drug: Giredestrant (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant (30 mg oral once daily)
Trial: 38537155
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of endocrine monotherapy (PCET)
Trial: 38537255
Drug: Adjuvanted 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 3.75 μg + AS03/2017 doses with delayed boost interval
Trial: 38537255
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of A(H7N9) IIV
Trial: 38537255
Drug: Adjuvanted second
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted second dose with longer interval
Trial: 38537255
Drug: AS03 adjuvant
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 adjuvant with second H7N9 IIV dose and extended boost interval to 4 months
Trial: 38537270
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (32 g)
Trial: 38537270
Drug: Plant protein
RxNorm normalized name: Kindersprout Plant Protein Chocolate Shake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant protein blend (32 g)
Trial: 38537315
Drug: Nivolumab (anti-PD1)
RxNorm normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (anti-PD1) administered intravenously until end of treatment (12 months), progression, unacceptable toxicity, or death.
Trial: 38537636
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4) plus standard HFrEF treatment
Trial: 38537636
Drug: Standard HFrEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HFrEF therapy alone
Trial: 38537676
Drug: Fesomersen 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesomersen 40 mg
Trial: 38537676
Drug: Fesomersen 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesomersen 80 mg
Trial: 38537676
Drug: Fesomersen 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesomersen 120 mg
Trial: 38537676
Drug: Fesomersen (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesomersen (all doses pooled)
Trial: 38537676
Drug: Fesomersen (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesomersen (all doses)
Trial: 38537773
Drug: OH2 oncolytic
RxNorm normalized name: OH2 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OH2 oncolytic viral therapy derived from herpes simplex virus 2 (HSV-2)
Trial: 38538057
Drug: Rescue intracranial
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue intracranial stenting (RIS) + best medical treatment (BMT)
Trial: 38538093
Drug: SNK01 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNK01 in combination with gemcitabine/carboplatin (n=6)
Trial: 38538093
Drug: SNK01 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNK01 in combination with cetuximab/gemcitabine/carboplatin (n=6)
Trial: 38538093
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (SNK01 + chemotherapy/cetuximab)
Trial: 38538161
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir or rilpivirine injections
Trial: 38538867
Drug: Therapeutic vaccine
RxNorm normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic vaccine encoding 20 shared neoantigens derived from selected common oncogenic driver mutations, combined with immune checkpoint inhibitors ipilimumab and nivolumab.
Trial: 38538867
Drug: Therapeutic vaccine
RxNorm normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic vaccine regimen (ChAd68 and samRNA) combined with immune checkpoint inhibitors.
Trial: 38539462
Drug: Composite intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite intervention consisting of non-hormonal pharmacotherapy, digital cognitive behavioral therapy for insomnia (dCBT-I) using Sleepio, self-management strategies via myPatientSpace mobile application, and nomination of an additional support person/partner
Trial: 38539914
Drug: Cosmetic treatment
RxNorm normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic treatment (cavitation peeling and sonophoresis with a commercial capillary repair serum)
Trial: 38540138
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice a day for 4 weeks
Trial: 38540555
Drug: Mood Lifters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood Lifters (ML) program
Trial: 38543926
Drug: Aerosolized Ad5-nCoV
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized Ad5-nCoV (Low-Dose)
Trial: 38543926
Drug: Intramuscular Ad5-nCoV
RxNorm normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Ad5-nCoV (Low-Dose)
Trial: 38543926
Drug: Intramuscular-Aerosolized Ad5-nCoV
RxNorm normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular-Aerosolized Ad5-nCoV (Low-Dose)
Trial: 38544798
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (GLP-1 receptor agonist + supervised exercise)
Trial: 38544834
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with chemotherapy plus trastuzumab for breast cancer patients
Trial: 38545090
Drug: BIO101 (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIO101 (350 mg BID)
Trial: 38545092
Drug: VBI-S (phospholipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-S (phospholipid nanoparticles) administered intravenously as boluses of 100 ml, 200 ml, 400 ml, and 800 ml until MAP goal was reached.
Trial: 38545092
Drug: VBI-S (phospholipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-S (phospholipid nanoparticles) administered intravenously.
Trial: 38545762
Drug: Daily Ecological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Ecological Momentary Assessments of Pain and Ability to Work
Trial: 38546375
Drug: Orelabrutinib, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib, dosage and duration not available
Trial: 38546803
Drug: Crisaborole QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole QD (once daily)
Trial: 38546821
Drug: 5-day fasting-mimicking
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day fasting-mimicking diet (FMD) programme, monthly cycles as an adjunct to regular care
Trial: 38546829
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film (SL-APO)
Trial: 38546944
Drug: EGFR-Erbitux receptor
RxNorm normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone
Trial: 38546960
Drug: Zanubrutinib (Bruton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanubrutinib (Bruton tyrosine kinase inhibitor)
Trial: 38547003
Drug: liso-cel (CAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liso-cel (CAR T cell therapy)
Trial: 38547135
Drug: Prolonged daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged daily motion modulated stimulation with a multichannel vestibulocochlear implant (VCI) prototype
Trial: 38547322
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (20 mg/ml, 1 ml)
Trial: 38547322
Drug: Placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride, 1 ml)
Trial: 38547892
Drug: Gedatolisib plus
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisib plus palbociclib and endocrine therapy (Letrozole for group A, Fulvestrant for groups B-D)
Trial: 38547892
Drug: Gedatolisib plus
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisib plus palbociclib and endocrine therapy
Trial: 38547892
Drug: Treatment-related serious
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related serious adverse events
Trial: 38547891
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 6.4 mg/kg (cohort 1)
Trial: 38547891
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 5.4 mg/kg (cohort 1A)
Trial: 38547893
Drug: LOAd703 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOAd703 combined with nab-paclitaxel (125 mg/m2) and gemcitabine
Trial: 38547895
Drug: Atezolizumab (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (800 mg intravenously every 2 weeks up to 1 year) plus modified docetaxel, cisplatin, and fluorouracil (mDCF) (eight cycles of 40 mg per m2 docetaxel, 75 mg per m2 cisplatin, and 750 mg per m2 fluorouracil)
Trial: 38548365
Drug: Daily diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily diary ratings of emotional state and pain severity (children only) at baseline and post
Trial: 38548367
Drug: Preadmission non-polypharmacy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preadmission non-polypharmacy (<5 medications)
Trial: 38548367
Drug: Preadmission polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preadmission polypharmacy (5-10 medications)
Trial: 38548367
Drug: Preadmission hyperpolypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preadmission hyperpolypharmacy (>10 medications)
Trial: 38548367
Drug: Higher level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher level of medication use
Trial: 38548404
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose azacitidine 50 mg/m plus venetoclax
Trial: 38548404
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose azacitidine plus venetoclax
Trial: 38550328
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccine intervention delivery
Trial: 38551394
Drug: TPST-1120 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPST-1120 monotherapy
Trial: 38551394
Drug: TPST-1120 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPST-1120 in combination with nivolumab
Trial: 38551501
Drug: CAR-GD2 T-cell
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-GD2 T-cell therapy